University Of Vermont Medical Center
- Type
- Teaching hospital
- Where
- Burlington, VT
- Medicare CCN
- 470003
- Received
- $3,029,679 in 1,224 records, 2019 ($156,829 general, $2,872,849 research)
- Source
- CMS Open Payments search ↗
On this site
- Business registration: THE UNIVERSITY OF VERMONT MEDICAL CENTER, INC. Fuzzy (name and state)
- Federal award recipient: UNIVERSITY OF VERMONT MEDICAL CENTER INC., THE Fuzzy (name and state)
- Nonprofit: UNIVERSITY OF VERMONT MEDICAL CENTER INC Fuzzy (name and state)
- Trademark owner: The University of Vermont Medical Center Inc. Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2019 | General payment | 27 | $156,829 |
| 2019 | Research payment | 1,197 | $2,872,849 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 1,197 | $2,872,849 |
| Gift | 5 | $47,787 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 6 | $39,460 |
| Grant | 2 | $37,250 |
| Education | 3 | $15,161 |
| Space rental or facility fees (teaching hospital only) | 7 | $8,950 |
| Consulting Fee | 1 | $8,000 |
| Food and Beverage | 3 | $219 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2019-12-31 | Philips North America LLC | $8,320 | Research payment | Cash or cash equivalent | Ingenia CX 3 0T Device, Devices | 2019 | |
| 2019-12-31 | AstraZeneca UK Limited | $4,531 | Research payment | In-kind items and services | TAGRISSO Drug, Oncology | AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non small Cell Lung Cancer | 2019 |
| 2019-12-31 | AstraZeneca Pharmaceuticals LP | $1,636 | Research payment | In-kind items and services | IMFINZI Drug, Oncology | A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Co | 2019 |
| 2019-12-31 | Spineology Inc. | $1,500 | Research payment | In-kind items and services | OptiMesh IDE Study Device, Orthopedics/Orthopedic Surgery | Spineology Clinical Outcomes Trial | 2019 |
| 2019-12-31 | Masimo Corporation | $37 | Education | In-kind items and services | rainbow Acoustic Monitoring Device, Devices | 2019 | |
| 2019-12-27 | Biosense Webster, Inc. | $35,000 | Grant | Cash or cash equivalent | 2019 | ||
| 2019-12-27 | Bayer Healthcare Pharmaceuticals Inc. | $1,400 | Research payment | Cash or cash equivalent | Non-Covered | BAY 94-8862 ph 3 conventional in diab nephropathy | 2019 |
| 2019-12-27 | Bayer Healthcare Pharmaceuticals Inc. | $1,400 | Research payment | Cash or cash equivalent | Non-Covered | BAY 94-8862 ph 3 conventional in diab nephropathy | 2019 |
| 2019-12-23 | Genentech, Inc. | $8,426 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | VA2 PHIII | 2019 |
| 2019-12-23 | Novo Nordisk AS | $3,129 | Research payment | Cash or cash equivalent | EX9536-4388 | 2019 | |
| 2019-12-19 | Intercept Pharmaceuticals, Inc. | $4,345 | Research payment | Cash or cash equivalent | 1009742 | 2019 | |
| 2019-12-19 | Novo Nordisk AS | $1,500 | Research payment | Cash or cash equivalent | EX9536-4388 | 2019 | |
| 2019-12-19 | ABBVIE INC. | $1,500 | Research payment | Cash or cash equivalent | Humira Biological, Immunology | P11-292 | 2019 |
| 2019-12-16 | Shockwave Medical, Inc | $500 | Research payment | Cash or cash equivalent | Prospective, Multicenter, Single-Arm, Global IDE Study of the Shockwave Coronary Intravascular Lithotripsy (IVL) System | 2019 | |
| 2019-12-13 | Genentech, Inc. | $1,500 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | VA2 PHIII YOSEMITE | 2019 |
| 2019-12-13 | AKEBIA THERAPEUTICS INC | $1,189 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2019 | |
| 2019-12-13 | AKEBIA THERAPEUTICS INC | $1,126 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2019 | |
| 2019-12-13 | AKEBIA THERAPEUTICS INC | $1,126 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2019 | |
| 2019-12-13 | AKEBIA THERAPEUTICS INC | $1,126 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2019 | |
| 2019-12-13 | AKEBIA THERAPEUTICS INC | $1,126 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2019 | |
| 2019-12-13 | EMD Serono, Inc. | $400 | Research payment | Cash or cash equivalent | Bavencio Biological, Oncology | EMR 100070-005 | 2019 |
| 2019-12-12 | AKEBIA THERAPEUTICS INC | $3,663 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2019 | |
| 2019-12-12 | Abbott Laboratories | $1,500 | Research payment | Cash or cash equivalent | Quadripolar CRT-D Device, Cardiac Arrhythmias and Heart Failure | Quadripolar Pacing Post Approval Study | 2019 |
| 2019-12-12 | AKEBIA THERAPEUTICS INC | $597 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2019 | |
| 2019-12-11 | United Therapeutics Corporation | $14,648 | Research payment | Cash or cash equivalent | TYVASO Drug, PAH | A MULTICENTER RANDOMIZED DOUBLE-BLINDED PLACEBO-CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF INHALED TREPROST | 2019 |
| 2019-12-11 | United Therapeutics Corporation | $912 | Research payment | Cash or cash equivalent | TYVASO Drug, PAH | AN OPEN-LABEL EXTENSION STUDY OF INHALED TREPROSTINIL IN SUBJECTS WITH PULMONARY HYPERTENSION DUE TO PARENCHYMAL LUNG DI | 2019 |
| 2019-12-11 | Roche TCRC, Inc. | $247 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHASE II STUDY IN EARLY STAGE PARKINSON S DISEASE PATIENTS | 2019 |
| 2019-12-11 | Roche TCRC, Inc. | $247 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHASE II STUDY IN EARLY STAGE PARKINSON S DISEASE PATIENTS | 2019 |
| 2019-12-09 | Medtronic Vascular, Inc. | $152 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | TAVR Low Risk | 2019 |
| 2019-12-09 | Medtronic Vascular, Inc. | $152 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | TAVR Low Risk | 2019 |
| 2019-12-09 | American Regent | $64 | Research payment | Cash or cash equivalent | INJECTAFER Drug, Anemia | Heart_FID | 2019 |
| 2019-12-09 | Merck Sharp & Dohme LLC | $48 | Research payment | In-kind items and services | BRIDION Drug, NEUROSCIENCE | A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pha | 2019 |
| 2019-12-09 | Merck Sharp & Dohme LLC | $39 | Research payment | In-kind items and services | BRIDION Drug, NEUROSCIENCE | A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pha | 2019 |
| 2019-12-09 | Merck Sharp & Dohme LLC | $23 | Research payment | In-kind items and services | BRIDION Drug, NEUROSCIENCE | A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pha | 2019 |
| 2019-12-09 | Merck Sharp & Dohme LLC | $5 | Research payment | In-kind items and services | BRIDION Drug, NEUROSCIENCE | A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pha | 2019 |
| 2019-12-09 | Merck Sharp & Dohme LLC | $0 | Research payment | In-kind items and services | BRIDION Drug, NEUROSCIENCE | A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pha | 2019 |
| 2019-12-05 | Intercept Pharmaceuticals, Inc. | $4,957 | Research payment | Cash or cash equivalent | 1009742 | 2019 | |
| 2019-12-05 | Spiration, Inc. | $3,500 | Research payment | Cash or cash equivalent | Spiration Valve System Device, EndoTherapy Products | A Prospective, Randomized, Controlled Multicenter clinical Trial to Evaluate the Safety and Effectiveness of the IBV Val | 2019 |
| 2019-12-05 | EMD Serono, Inc. | $1,462 | Research payment | Cash or cash equivalent | Bavencio Biological, Oncology | EMR 100070-001 | 2019 |
| 2019-12-04 | Pharmacyclics LLC, an AbbVie Company | $3,464 | Research payment | Cash or cash equivalent | Ibrutinib Drug, Oncology | PCYC-1103-CA | 2019 |
| 2019-12-04 | Medtronic Vascular, Inc. | $1,500 | Research payment | Cash or cash equivalent | CoreValve CAS | 2019 | |
| 2019-12-04 | Medtronic Vascular, Inc. | $1,500 | Research payment | Cash or cash equivalent | CoreValve US Pivotal | 2019 | |
| 2019-12-03 | Novo Nordisk AS | $3,250 | Research payment | Cash or cash equivalent | NN9535-4321 | 2019 | |
| 2019-12-03 | Novo Nordisk AS | $2,500 | Research payment | Cash or cash equivalent | NN9535-4321 | 2019 | |
| 2019-12-03 | Novo Nordisk AS | $2,332 | Research payment | Cash or cash equivalent | EX9536-4388 | 2019 | |
| 2019-12-03 | Novo Nordisk AS | $1,500 | Research payment | Cash or cash equivalent | NN9535-4321 | 2019 | |
| 2019-12-03 | AKEBIA THERAPEUTICS INC | $1,276 | Research payment | Cash or cash equivalent | AKB-6548-CI-0017 | 2019 | |
| 2019-12-03 | AKEBIA THERAPEUTICS INC | $1,276 | Research payment | Cash or cash equivalent | AKB-6548-CI-0017 | 2019 | |
| 2019-12-03 | AKEBIA THERAPEUTICS INC | $1,070 | Research payment | Cash or cash equivalent | AKB-6548-CI-0017 | 2019 | |
| 2019-12-03 | AKEBIA THERAPEUTICS INC | $1,070 | Research payment | Cash or cash equivalent | AKB-6548-CI-0017 | 2019 | |
| 2019-12-03 | AKEBIA THERAPEUTICS INC | $1,070 | Research payment | Cash or cash equivalent | AKB-6548-CI-0017 | 2019 | |
| 2019-12-03 | AKEBIA THERAPEUTICS INC | $1,070 | Research payment | Cash or cash equivalent | AKB-6548-CI-0017 | 2019 | |
| 2019-12-03 | AKEBIA THERAPEUTICS INC | $1,070 | Research payment | Cash or cash equivalent | AKB-6548-CI-0017 | 2019 | |
| 2019-12-03 | AKEBIA THERAPEUTICS INC | $1,070 | Research payment | Cash or cash equivalent | AKB-6548-CI-0017 | 2019 | |
| 2019-12-03 | AKEBIA THERAPEUTICS INC | $724 | Research payment | Cash or cash equivalent | AKB-6548-CI-0017 | 2019 | |
| 2019-12-03 | AKEBIA THERAPEUTICS INC | $724 | Research payment | Cash or cash equivalent | AKB-6548-CI-0017 | 2019 | |
| 2019-12-02 | AstraZeneca UK Limited | $4,305 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TAGRISSO Drug, Oncology | 2019 | |
| 2019-11-26 | Olympus America Inc. | $5,124 | Education | In-kind items and services | Olympus Capital Accessories Device, ENT Products | 2019 | |
| 2019-11-25 | Roche TCRC, Inc. | $100,990 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHASE II STUDY IN EARLY STAGE PARKINSON S DISEASE PATIENTS | 2019 |
| 2019-11-25 | Intercept Pharmaceuticals, Inc. | $3,912 | Research payment | Cash or cash equivalent | OCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY | 1011866 | 2019 |
| 2019-11-25 | Janssen Research & Development, LLC | $953 | Research payment | Cash or cash equivalent | REMICADE Biological, Immunology | A multi center prospective long term observational registry of pediatric patients with IBS | 2019 |
| 2019-11-25 | SANOFI US SERVICES INC. | $769 | Research payment | Cash or cash equivalent | SAR439954 Drug | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotaglif | 2019 |
| 2019-11-22 | Bayer Healthcare Pharmaceuticals Inc. | $6,387 | Research payment | Cash or cash equivalent | Non-Covered | BAY 94-8862 ph 3 conventional in diab nephropathy | 2019 |
| 2019-11-21 | Procept Biorobotics Corporation | $9,500 | Research payment | Cash or cash equivalent | AquaBeam Robotic System Device, Urology | WATER II (TP0124) | 2019 |
| 2019-11-21 | ABBVIE INC. | $772 | Research payment | Cash or cash equivalent | Humira Biological, Immunology | P11-282 | 2019 |
| 2019-11-21 | Pharmacyclics LLC, an AbbVie Company | $404 | Research payment | Cash or cash equivalent | Ibrutinib Drug, Oncology | PCYC-1145-LT | 2019 |
| 2019-11-20 | Gilead Sciences, Inc. | $8,578 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and S | 2019 | |
| 2019-11-20 | Gilead Sciences, Inc. | $111 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilof | 2019 | |
| 2019-11-20 | Novo Nordisk AS | $24 | Research payment | In-kind items and services | EX9536-4388 | 2019 | |
| 2019-11-19 | EMD Serono, Inc. | $3,500 | Research payment | Cash or cash equivalent | Mavenclad Biological, Neurology | MS700568-0078 | 2019 |
| 2019-11-19 | Novo Nordisk AS | $108 | Research payment | In-kind items and services | EX9536-4388 | 2019 | |
| 2019-11-19 | Novo Nordisk AS | $83 | Research payment | In-kind items and services | EX9536-4388 | 2019 | |
| 2019-11-19 | Novo Nordisk AS | $64 | Research payment | In-kind items and services | EX9536-4388 | 2019 | |
| 2019-11-19 | Novo Nordisk AS | $44 | Research payment | In-kind items and services | EX9536-4388 | 2019 | |
| 2019-11-19 | Novo Nordisk AS | $24 | Research payment | In-kind items and services | EX9536-4388 | 2019 | |
| 2019-11-19 | Novo Nordisk AS | $23 | Research payment | In-kind items and services | EX9536-4388 | 2019 | |
| 2019-11-19 | Novo Nordisk AS | $15 | Research payment | In-kind items and services | EX9536-4388 | 2019 | |
| 2019-11-19 | Novo Nordisk AS | $10 | Research payment | In-kind items and services | EX9536-4388 | 2019 | |
| 2019-11-18 | Boston Scientific Corporation | $1,500 | Research payment | Cash or cash equivalent | SYNERGY Device, STENTS | EVOLVE SHORT DAPT | 2019 |
| 2019-11-18 | AKEBIA THERAPEUTICS INC | $1,253 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2019 | |
| 2019-11-18 | AKEBIA THERAPEUTICS INC | $1,215 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2019 | |
| 2019-11-18 | AKEBIA THERAPEUTICS INC | $1,189 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2019 | |
| 2019-11-18 | AKEBIA THERAPEUTICS INC | $1,126 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2019 | |
| 2019-11-18 | AKEBIA THERAPEUTICS INC | $1,126 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2019 | |
| 2019-11-18 | AKEBIA THERAPEUTICS INC | $1,070 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2019 | |
| 2019-11-15 | Acorda Therapeutics, Inc | $1,945 | Research payment | Cash or cash equivalent | SYN120 a Dual 5-HT65-HT2A Antagonist Proof of Concept Study to Evaluate Its Safety, Tolerability and Efficacy in Parkins | 2019 | |
| 2019-11-14 | Grifols Biologicals LLC | $4,050 | Research payment | Cash or cash equivalent | Flebogamma DIF Biological, Immnunology | A Multicenter, Prospective, Randomized, Placebo-controlled, Double-blind, ParallelGroup Clinical Trial to Assess the Eff | 2019 |
| 2019-11-14 | Grifols Biologicals LLC | $2,890 | Research payment | Cash or cash equivalent | Flebogamma DIF Biological, Immnunology | A Multicenter, Prospective, Randomized, Placebo-controlled, Double-blind, ParallelGroup Clinical Trial to Assess the Eff | 2019 |
| 2019-11-14 | Grifols Biologicals LLC | $1,500 | Research payment | Cash or cash equivalent | Flebogamma DIF Biological, Immnunology | A Multicenter, Prospective, Randomized, Placebo-controlled, Double-blind, ParallelGroup Clinical Trial to Assess the Eff | 2019 |
| 2019-11-13 | Orion Corporation | $2,675 | Research payment | Cash or cash equivalent | Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS | 2019 | |
| 2019-11-13 | SANOFI US SERVICES INC. | $629 | Research payment | Cash or cash equivalent | SAR439954 Drug | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotaglif | 2019 |
| 2019-11-12 | SANOFI US SERVICES INC. | $2,637 | Research payment | Cash or cash equivalent | SAR439954 Drug | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotaglif | 2019 |
| 2019-11-12 | AstraZeneca UK Limited | $1,644 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TAGRISSO Drug, Oncology | 2019 | |
| 2019-11-12 | SANOFI US SERVICES INC. | $1,632 | Research payment | Cash or cash equivalent | SAR439954 Drug | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotaglif | 2019 |
| 2019-11-12 | Novo Nordisk AS | $195 | Research payment | Cash or cash equivalent | EX9536-4388 | 2019 | |
| 2019-11-11 | Abbott Laboratories | $100 | Research payment | Cash or cash equivalent | Xience V coronary stent system Device, Vascular | DAPT study | 2019 |
| 2019-11-08 | Medtronic Vascular, Inc. | $1,794 | Research payment | Cash or cash equivalent | TAVR Low Risk CAS | 2019 | |
| 2019-11-08 | Medtronic Vascular, Inc. | $1,794 | Research payment | Cash or cash equivalent | TAVR Low Risk CAS | 2019 | |
| 2019-11-07 | ABBVIE INC. | $1,500 | Research payment | Cash or cash equivalent | Humira Biological, Immunology | P11-282 | 2019 |
| 2019-11-05 | Shockwave Medical, Inc | $195 | Research payment | Cash or cash equivalent | Prospective, Multicenter, Single-Arm, Global IDE Study of the Shockwave Coronary Intravascular Lithotripsy (IVL) System | 2019 | |
| 2019-11-04 | Medtronic Vascular, Inc. | $4,056 | Research payment | Cash or cash equivalent | ECG Belt | 2019 | |
| 2019-11-04 | SANOFI US SERVICES INC. | $2,728 | Research payment | Cash or cash equivalent | SAR439954 Drug | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotaglif | 2019 |
| 2019-11-04 | Bayer Healthcare Pharmaceuticals Inc. | $1,812 | Research payment | Cash or cash equivalent | Non-Covered | BAY94-8862 ph 3 conventional in diabetic nephropathy | 2019 |
| 2019-11-04 | SANOFI US SERVICES INC. | $1,500 | Research payment | Cash or cash equivalent | SAR439954 Drug | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotaglif | 2019 |
| 2019-11-04 | Boston Scientific Corporation | $1,500 | Research payment | Cash or cash equivalent | WATCHMAN Device, STRUCTURAL HEART | CAP2 | 2019 |
| 2019-11-04 | AKEBIA THERAPEUTICS INC | $1,255 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2019 | |
| 2019-11-04 | AKEBIA THERAPEUTICS INC | $1,227 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2019 | |
| 2019-11-04 | AKEBIA THERAPEUTICS INC | $1,227 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2019 | |
| 2019-11-04 | Bayer Healthcare Pharmaceuticals Inc. | $1,190 | Research payment | Cash or cash equivalent | Non-Covered | BAY94-8862 ph 3 conventional in diabetic nephropathy | 2019 |
| 2019-11-04 | Bayer Healthcare Pharmaceuticals Inc. | $1,190 | Research payment | Cash or cash equivalent | Non-Covered | BAY94-8862 ph 3 conventional in diabetic nephropathy | 2019 |
| 2019-11-04 | AKEBIA THERAPEUTICS INC | $1,126 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2019 | |
| 2019-11-04 | AKEBIA THERAPEUTICS INC | $1,126 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2019 | |
| 2019-11-04 | AKEBIA THERAPEUTICS INC | $1,126 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2019 | |
| 2019-11-04 | AKEBIA THERAPEUTICS INC | $1,126 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2019 | |
| 2019-11-04 | AKEBIA THERAPEUTICS INC | $1,126 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2019 | |
| 2019-11-04 | AKEBIA THERAPEUTICS INC | $1,126 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2019 | |
| 2019-11-04 | AKEBIA THERAPEUTICS INC | $1,126 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2019 | |
| 2019-11-04 | AKEBIA THERAPEUTICS INC | $1,126 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2019 | |
| 2019-11-04 | AKEBIA THERAPEUTICS INC | $1,070 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2019 | |
| 2019-11-04 | AKEBIA THERAPEUTICS INC | $1,070 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2019 | |
| 2019-11-04 | AKEBIA THERAPEUTICS INC | $1,070 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2019 | |
| 2019-11-04 | SANOFI US SERVICES INC. | $816 | Research payment | Cash or cash equivalent | SAR439954 Drug | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotaglif | 2019 |
| 2019-11-04 | AKEBIA THERAPEUTICS INC | $194 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2019 | |
| 2019-11-04 | AKEBIA THERAPEUTICS INC | $169 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2019 | |
| 2019-11-04 | AKEBIA THERAPEUTICS INC | $169 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2019 | |
| 2019-11-04 | AKEBIA THERAPEUTICS INC | $131 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2019 | |
| 2019-11-04 | AKEBIA THERAPEUTICS INC | $131 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2019 | |
| 2019-11-04 | AKEBIA THERAPEUTICS INC | $128 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2019 | |
| 2019-11-04 | AKEBIA THERAPEUTICS INC | $102 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2019 | |
| 2019-11-04 | AKEBIA THERAPEUTICS INC | $102 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2019 | |
| 2019-11-04 | AKEBIA THERAPEUTICS INC | $102 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2019 | |
| 2019-11-04 | AKEBIA THERAPEUTICS INC | $102 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2019 | |
| 2019-11-04 | AKEBIA THERAPEUTICS INC | $102 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2019 | |
| 2019-11-04 | AKEBIA THERAPEUTICS INC | $102 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2019 | |
| 2019-11-04 | AKEBIA THERAPEUTICS INC | $102 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2019 | |
| 2019-11-04 | AKEBIA THERAPEUTICS INC | $101 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2019 | |
| 2019-11-04 | AKEBIA THERAPEUTICS INC | $101 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2019 | |
| 2019-11-04 | AKEBIA THERAPEUTICS INC | $101 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2019 | |
| 2019-11-04 | AKEBIA THERAPEUTICS INC | $94 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2019 | |
| 2019-11-04 | AKEBIA THERAPEUTICS INC | $68 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2019 | |
| 2019-11-04 | AKEBIA THERAPEUTICS INC | $68 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2019 | |
| 2019-11-04 | AKEBIA THERAPEUTICS INC | $68 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2019 | |
| 2019-11-04 | AKEBIA THERAPEUTICS INC | $34 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2019 | |
| 2019-11-04 | AKEBIA THERAPEUTICS INC | $34 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2019 | |
| 2019-11-04 | AKEBIA THERAPEUTICS INC | $34 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2019 | |
| 2019-11-01 | Abbott Laboratories | $10,200 | Research payment | Cash or cash equivalent | Xience V coronary stent system Device, Vascular | DAPT study | 2019 |
| 2019-11-01 | Medtronic Vascular, Inc. | $975 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | TAVR Low Risk | 2019 |
| 2019-11-01 | Medtronic Vascular, Inc. | $975 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | TAVR Low Risk | 2019 |
| 2019-10-31 | Medtronic Vascular, Inc. | $2,528 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | CoreValve EUS | 2019 |
| 2019-10-30 | Abbott Laboratories | $3,404 | Research payment | Cash or cash equivalent | His bundle pacing (HBP) Device, Cardiac Arrhythmias and Heart Failure | His Bundle Pacing Pacemaker Mapping Registry | 2019 |
| 2019-10-29 | Novo Nordisk AS | $1,405 | Research payment | Cash or cash equivalent | EX9536-4388 | 2019 | |
| 2019-10-29 | Medtronic Vascular, Inc. | $300 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | CoreValve SURTAVI | 2019 |
| 2019-10-25 | Bayer Healthcare Pharmaceuticals Inc. | $1,190 | Research payment | Cash or cash equivalent | Non-Covered | BAY 94-8862 ph 3 conventional in diab nephropathy | 2019 |
| 2019-10-24 | SANOFI PASTEUR INC. | $45,310 | Research payment | Cash or cash equivalent | YELLOW FEVER Drug | STA00011 Stamaril Yellow Fever | 2019 |
| 2019-10-24 | Genentech, Inc. | $10,251 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | VA2 PHIII YOSEMITE | 2019 |
| 2019-10-24 | UCB GmbH | $1,025 | Research payment | Cash or cash equivalent | A MULTICENTER, RANDOMIZED, INVESTIGATOR - AND SUBJECT-BLIND, PLACEBO-CONTROLLED, TREATMENT SEQUENCE STUDY EVALUATING THE | 2019 | |
| 2019-10-23 | Abbott Laboratories | $9,945 | Research payment | Cash or cash equivalent | Cardiovascular- Research only Device, Cardiac Arrhythmias and Heart Failure | AMPLATZER Amulet Left Atrial Appendage Occluder Randomized Controlled Trial | 2019 |
| 2019-10-23 | Intercept Pharmaceuticals, Inc. | $5,568 | Research payment | Cash or cash equivalent | 1009742 | 2019 | |
| 2019-10-23 | Medtronic Vascular, Inc. | $3,343 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | TAVR Low Risk | 2019 |
| 2019-10-23 | Medtronic Vascular, Inc. | $3,343 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | TAVR Low Risk | 2019 |
| 2019-10-23 | Medtronic Vascular, Inc. | $2,232 | Research payment | Cash or cash equivalent | TAVR Low Risk CAS | 2019 | |
| 2019-10-23 | Medtronic Vascular, Inc. | $2,232 | Research payment | Cash or cash equivalent | TAVR Low Risk CAS | 2019 | |
| 2019-10-23 | ABBVIE INC. | $1,500 | Research payment | Cash or cash equivalent | Humira Biological, Immunology | P10-262 | 2019 |
| 2019-10-23 | Merck Sharp & Dohme LLC | $521 | Research payment | In-kind items and services | BRIDION Drug, NEUROSCIENCE | A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pha | 2019 |
| 2019-10-22 | Medtronic Vascular, Inc. | $7,663 | Research payment | Cash or cash equivalent | Viva Device, Implantable Cardioverter Defibrillators (ICDs) | AdaptResponse | 2019 |
| 2019-10-22 | Medtronic Vascular, Inc. | $4,446 | Research payment | Cash or cash equivalent | CoreValve CAS | 2019 | |
| 2019-10-21 | F. Hoffmann-La Roche AG | $16,715 | Research payment | Cash or cash equivalent | OCREVUS Biological, Immunology | OCRELIZUMAB IN PATIENTS WITH RMS | 2019 |
| 2019-10-18 | Shire North American Group Inc | $2,730 | Research payment | Cash or cash equivalent | NATPARA (PARATHYROID HORMONE) Drug, INTERNAL MEDICINE | PARADIGHM A NATURAL HISTORY REGISTRY FOR PATIENTS WITH CHRONIC HYPOPARATHYROIDISM | 2019 |
| 2019-10-18 | AKEBIA THERAPEUTICS INC | $1,070 | Research payment | Cash or cash equivalent | AKB-6548-CI-0017 | 2019 | |
| 2019-10-18 | AKEBIA THERAPEUTICS INC | $1,070 | Research payment | Cash or cash equivalent | AKB-6548-CI-0017 | 2019 | |
| 2019-10-18 | AKEBIA THERAPEUTICS INC | $1,070 | Research payment | Cash or cash equivalent | AKB-6548-CI-0017 | 2019 | |
| 2019-10-18 | AKEBIA THERAPEUTICS INC | $1,070 | Research payment | Cash or cash equivalent | AKB-6548-CI-0017 | 2019 | |
| 2019-10-18 | AKEBIA THERAPEUTICS INC | $1,070 | Research payment | Cash or cash equivalent | AKB-6548-CI-0017 | 2019 | |
| 2019-10-18 | AKEBIA THERAPEUTICS INC | $1,070 | Research payment | Cash or cash equivalent | AKB-6548-CI-0017 | 2019 | |
| 2019-10-18 | AKEBIA THERAPEUTICS INC | $1,070 | Research payment | Cash or cash equivalent | AKB-6548-CI-0017 | 2019 | |
| 2019-10-18 | AKEBIA THERAPEUTICS INC | $1,070 | Research payment | Cash or cash equivalent | AKB-6548-CI-0017 | 2019 | |
| 2019-10-18 | AKEBIA THERAPEUTICS INC | $1,070 | Research payment | Cash or cash equivalent | AKB-6548-CI-0017 | 2019 | |
| 2019-10-18 | AKEBIA THERAPEUTICS INC | $1,070 | Research payment | Cash or cash equivalent | AKB-6548-CI-0017 | 2019 | |
| 2019-10-17 | Regeneron Pharmaceuticals, Inc. | $14,648 | Research payment | Cash or cash equivalent | EYLEA Biological, OPHTHALMOLOGY | A PHASE 3, DOUBLE-MASKED, RANDOMIZED STUDY OF THE EFFICACY AND SAFETY OF INTRAVITREAL AFLIBERCEPT INJECTION IN PATIENTS | 2019 |
| 2019-10-17 | Intercept Pharmaceuticals, Inc. | $1,586 | Research payment | Cash or cash equivalent | OCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY | 1011866 | 2019 |
| 2019-10-17 | Spiration, Inc. | $974 | Research payment | Cash or cash equivalent | Spiration Valve System Device, EndoTherapy Products | A Prospective, Randomized, Controlled Multicenter clinical Trial to Evaluate the Safety and Effectiveness of the IBV Val | 2019 |
| 2019-10-15 | ABBVIE INC. | $2,500 | Research payment | Cash or cash equivalent | Rinvoq Biological, Immunology | M16-852 | 2019 |
| 2019-10-15 | SANOFI US SERVICES INC. | $816 | Research payment | Cash or cash equivalent | SAR439954 Drug | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotaglif | 2019 |
| 2019-10-15 | Eli Lilly and Company | $122 | Research payment | In-kind items and services | A MULTICENTER, OPEN-LABEL, RANDOMIZED-CONTROLLED STUDY OF ABEMACICLIB, A CDK4 AND 6 INHIBITOR, IN COMBINATION WITH FULVE | 2019 | |
| 2019-10-14 | AKEBIA THERAPEUTICS INC | $630 | Research payment | Cash or cash equivalent | AKB-6548-CI-0017 | 2019 | |
| 2019-10-14 | AKEBIA THERAPEUTICS INC | $455 | Research payment | Cash or cash equivalent | AKB-6548-CI-0017 | 2019 | |
| 2019-10-14 | AKEBIA THERAPEUTICS INC | $450 | Research payment | Cash or cash equivalent | AKB-6548-CI-0017 | 2019 | |
| 2019-10-14 | AKEBIA THERAPEUTICS INC | $432 | Research payment | Cash or cash equivalent | AKB-6548-CI-0017 | 2019 | |
| 2019-10-10 | Merck Sharp & Dohme LLC | $9,490 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand | 2019 |
| 2019-10-10 | Regeneron Pharmaceuticals, Inc. | $7,883 | Research payment | Cash or cash equivalent | EYLEA Biological, OPHTHALMOLOGY | A PHASE 3, DOUBLE-MASKED, RANDOMIZED STUDY OF THE EFFICACY AND SAFETY OF INTRAVITREAL AFLIBERCEPT INJECTION IN PATIENTS | 2019 |
| 2019-10-10 | Abbott Laboratories | $620 | Research payment | Cash or cash equivalent | AMPLATZER Amulet Left Atrial Appendage Occlude Device, Cardiac Arrhythmias and Heart Failure | AMPLATZER Amulet Left Atrial Appendage Occluder Randomized Controlled Trial | 2019 |
| 2019-10-09 | American Regent | $10,396 | Research payment | Cash or cash equivalent | INJECTAFER Drug, Anemia | Heart_FID | 2019 |
| 2019-10-09 | Intercept Pharmaceuticals, Inc. | $4,802 | Research payment | Cash or cash equivalent | 1009742 | 2019 | |
| 2019-10-08 | Orion Corporation | $5,206 | Research payment | Cash or cash equivalent | Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS | 2019 | |
| 2019-10-08 | Orion Corporation | $1,013 | Research payment | Cash or cash equivalent | Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS | 2019 | |
| 2019-10-07 | Medtronic Vascular, Inc. | $2,500 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | CoreValve EUS | 2019 |
| 2019-10-07 | SANOFI US SERVICES INC. | $2,500 | Research payment | Cash or cash equivalent | SAR439977 Drug | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatid | 2019 |
| 2019-10-04 | Medtronic, Inc. | $11,810 | Research payment | Cash or cash equivalent | Attain Device, Leads | PSR-CVG | 2019 |
| 2019-10-04 | Mallinckrodt Enterprises LLC | $500 | Research payment | Cash or cash equivalent | ACTHAR Biological, AUTOIMMUNE AND RARE DISEASE | A DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF H.P. ACTHAR GEL IN THE MANAGEMENT OF AMYOTROPHIC LATERAL SCLEROSIS | 2019 |
| 2019-10-03 | Janssen Research & Development, LLC | $12,867 | Research payment | Cash or cash equivalent | MS PHASE 2 EXTENSION HQ - AC-058B202 | 2019 |
The latest 200 records of 1,224.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Burlington, VT, county Chittenden County, VT, state Vermont; placed by its city name.
| Measure | Place (city or town) Burlington, VT | County Chittenden County, VT | State Vermont |
|---|---|---|---|
| Population B01003 | 44,675 | 169,758 | 647,106 |
| Population, 2020 census P1 | 44,743 | 168,323 | 643,077 |
| Median age B01002 | 26.8 | 37.3 | 43.1 |
| Under 18 B01001 | 11.1% | 17.2% | 17.9% |
| 65 and over B01001 | 12.1% | 16.9% | 21.4% |
| Households B11001 | 17,504 | 71,456 | 273,416 |
| Foreign born B05002 | 7.1% | 7.9% | 4.3% |
| Median household income B19013 | $71,109 | $96,759 | $81,203 |
| Median family income B19113 | $130,243 | $131,883 | $105,211 |
| Per capita income B19301 | $40,192 | $52,322 | $46,500 |
| Poverty rate B17001 | 20.5% | 9.7% | 10.1% |
| Unemployment rate B23025 | 4.3% | 3.2% | 3.6% |
| Civilian labor force B23025 | 26,390 | 101,136 | 352,132 |
| Mean commute (minutes) B08013 | 18.7 | 21.1 | 23.5 |
| Bachelor's degree or higher B15003 | 60.5% | 56.8% | 43.8% |
| Housing units B25001 | 18,079 | 74,888 | 339,042 |
| Owner-occupied B25003 | 41.5% | 63.9% | 73.2% |
| Renters B25003 | 58.5% | 36.1% | 26.8% |
| Median home value B25077 | $444,800 | $439,200 | $316,600 |
| Median gross rent B25064 | $1,649 | $1,646 | $1,234 |
| White, not Hispanic B03002 | 84.1% | 85.5% | 89.9% |
| Black B03002 | 2.9% | 2.3% | 1.1% |
| Hispanic or Latino B03002 | 2.8% | 2.9% | 2.6% |
| Asian B03002 | 4.2% | 4.4% | 1.8% |
| American Indian and Alaska Native B03002 | 0.0% | 0.1% | 0.1% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Burlington, VT.
Comments